Data as of Q4 2025 (Dec 31, 2025)

GINKGO BIOWORKS HOLDINGS, INC.

(DNA)

Financial Statements · SEC EDGAR XBRL

Revenue
$170.2M
-25.1%
Net Income
-$313K
+42.8%
EPS
$-5.64
+46.5%
Op. Income
-$315.3M
+43.7%
FCF
-$178.7M
+53.2%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Operating Expenses & Income
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Interest Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
$170.2M
$227.0M
$251.5M
$477.7M
$313.8M
$170.2M
$227.0M
$251.5M
$477.7M
$313.8M
$243.8M
$424.1M
$580.6M
$1.05B
$1.15B
$485.4M
$786.8M
$1.12B
$2.69B
$2.14B
-$315.3M
-$559.8M
-$864.4M
-$2.21B
-$1.83B
-
-
$93K
$106K
$2.4M
$1.7M
$12.2M
-$28.5M
$87.6M
-$9.7M
-$313.6M
-$547.5M
-$892.9M
-$2.12B
-$1.84B
-$837K
-$479K
-$71K
-$15.0M
-$1.5M
-$313K
-$547K
-$893K
-$2.1M
-$1.8M
$-5.64
$-10.54
$-18.37
$-50.15
$-1.35
$-5.64
$-10.54
$-18.37
$-50.20
$-1.39
55.5M
51.9M
48.6M
42.0M
1.36B